SecBot SecBot
SECBOTREPLAY Home › Report › MESO

MESO · Mesoblast highlighted its commercial strategy as Ryoncil® nears $100M…

Mesoblast Limited · PRESS-RELEASE filed Apr 8, 2026 at 09:07 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 8, 2026 at 09:07 ET

Mesoblast highlighted its commercial strategy as Ryoncil® nears $100M in net revenue since launch, announced the close of enrollment in its Phase 3 trial for chronic low back pain (CLBP), received FDA clearance for a registrational trial in pediatric Duchenne muscular dystrophy (DMD), and acquired a patented CAR technology platform from Mayo Clinic to enhance its MSC therapies. The updates were shared during its R&D Day webcast.

  • Ryoncil® is approaching $100 million in net revenue since its launch last year.
  • Enrollment in the Phase 3 trial for chronic low back pain (CLBP) is closing at the end of the month.
  • FDA cleared an IND to proceed directly to a registrational trial for Ryoncil® in pediatric DMD.
  • Central IRB approval obtained for adult SR-aGvHD trial; first sites to activate this quarter.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access